Table 5. Nasal virus-specific secretory IgA responses at Day 39±3 after first nasal administration of trivalent Proteosome influenza vaccine.

Dose group	A/New Caledonia (H1N1)	A/Panama (H3N2)	B Strain†
	Geometric mean fold rise (95% CI)	Geometric mean fold rise (95% CI)	Geometric mean fold rise (95% CI)
	Day 39±3	Day 39±3	Day 39±3
Placebo	0.93 (0.77–1.12)	1.04 (0.90–1.21)	1.02 (0.88–1.17)
15 μg x 2	4.08 (2.87–5.7)**	4.07 (3.10–5.36)**	2.66 (2.03–3.49)**
30 μg x 1	1.50 (1.13–1.99)*	1.66 (1.33–2.08)*	1.24 (1.03–1.51)*
30 μg x 2	3.93 (2.97–5.”20)**	3.28 (2.46–4.37)**	2.45 (1.91–3.14)**

†B Strain: B/Victoria in Study 1, B/Shandong in Study 2

*p< 0.05 compared to placebo

**p< 0.0001 compared to placebo

There were also significant (p<0.0001) geometric mean fold rises in nasal sIgA specific to A/New Caledonia/20/1999 (H1N1) and the B strains (B/Victoria in Study 1 and B/Shandong in Study 2) at Day 39 for both active two dose groups, with the greatest increases in the 15 μg x 2 treatment group. The increases were lowest in the 30 μg x 1 treatment groups but still significant, p = 0.0007 for A/New Caledonia/20/99 and p = 0.026 for the B strains.

The active two dose groups both showed significantly (p<0.0001) higher increases than the single active dose group for all three strains.